IDH1 and cancer: A significant increasing trend in the VAP-1+/CD163+ M2 phenotype was observed in cancer specimens for age (p = 0.0164), WHO grade (p < 0.0001), patient survival (p < 0.0001) and IDH mutations (p = 0.0053, Table 2).